Cadila buys German animal drug company from ICICI Venture HSA Pollath and De Brauw advise

Drug maker Cadila Healthcare through its fully-owned subsidiary Zydus Animal Health Ltd. (ZAHL) has signed a share purchase agreement with private equity fund ICICI Venture to acquire 100 percent shareholding of Germany-based Bremer Pharma GmbH for an undisclosed amount.

The transaction involved sale of entities across three jurisdictions i.e. India, Netherlands and Germany.

HSA Advocates advised ICICI Venture with a team led by Partner Aparajit Bhattacharya along with Senior Associate Harvinder Singh and Associate Sumedha Dutta.

Cadila was advised by their in-house legal team and were assisted by International firms P+P Pöllath + Partners from Germany and De Brauw Blackstone Westbroek from Netherland.

According to ET, the agreement includes the transfer of all key assets, people, brands and export contracts of Bremer. The acquisition will help ZAHL expand its animal health business and gain strategic access to the key markets across Europe, South America, Asia and Africa. The global animal health business is valued at $20 billion.

Bremer Pharma is into poultry and livestock business and has over 500 registrations as well as extensive network of distributors in more than 50 countries.

ZAHL is India’s leading animal healthcare company and a market leader in various therapeutic segments which include antibacterials, NSAIDs, antimastitis, tonics and poultry vaccines.